Search
  • Michelle Laracuente

University of Penn Has Done It Again!

University of #Penn refuses to stop innovating. After having introduced CAR-T to the fight against #cancer, another Penn team has developed an a related technology which has produced positive results in animal trials.

Chimeric Antigen Receptor T cells, or CAR-T, has demonstrated success in treating #bloodcancer, but falls short against solid tumors. The Penn team's new technology, Chimeric Antigen Receptor Macrophages or CAR-M, leverages a similar process of altering the patient's own immune cells to target the cancer cells. Results from the animal model showed positive effects against solid tumors and the researchers report preparing for a phase I trial to begin this year.

#Kognitic will be monitoring the emergence of CAR-M trials and providing clients with real-time data and analytics for this new modality!


#Oncology #Pharma #Tumors #Data #Analytics #CuttingEdge #Automated #Innovation #CancerResearch #Ai


https://www.fiercebiotech.com/research/abbvie-backed-carisma-s-car-m-tech-shrinks-tumors-mouse-models-ovarian-cancer

1 view

© 2018 Kognitic, Inc.

  • LinkedIn Social Icon
  • Twitter Social Icon